Over Half Of Cannabis Users With Parkinson’s Disease Report Clinical Benefits

A survey in Germany found over 8% of patients with Parkinson’s disease are using cannabis products and more than half experienced beneficial clinical effects, reports the Journal of Parkinson’s Disease

NETHERLANDS:  With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD). According to results of a survey of PD patients in Germany in the Journal of Parkinson’s Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect.

Cannabis products containing THC (tetrahydrocannabinol, the main psychoactive compound of cannabis) can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms. CBD (pure cannabidiol, derived directly from the hemp plant, a cousin of the marijuana plant) is available without a prescription from pharmacies and on the internet.

“Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” explained lead investigator Prof. Dr. med. Carsten Buhmann, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. “PD patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient and which symptoms. We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”

Investigators aimed to assess patient perceptions of medicinal cannabis as well as evaluate the experiences of patients already using cannabis products. They performed a nationwide, cross-sectional, questionnaire-based survey among members of the German Parkinson Association (Deutsche Parkinson Vereinigung e.V.), which is the largest consortium of PD patients in German-speaking countries with nearly 21,000 members. Questionnaires were sent out in April 2019 with the association’s membership journal and were also distributed in the investigators’ clinic.

Over 1,300 questionnaires were analyzed; results showed that interest in the PD community in medical cannabis was high, but knowledge about different types of products was limited. Fifty-one percent of respondents were aware of the legality of medicinal cannabis, and 28% were aware of the various routes of administration (inhaling versus oral administration), but only 9% were aware of the difference between THC and CBD.

More than 8% of patients were already using cannabinoids and more than half of these users (54%) reported that it had a beneficial clinical effect. The overall tolerability was good. Over 40% of users reported that it helped manage pain and muscle cramps, and more than 20% of users reported a reduction of stiffness (akinesia), freezing, tremor, depression, anxiety, and restless legs. Patients reported that inhaled cannabis products containing THC were more efficient in treating stiffness than oral products containing CBD but were slightly less well tolerated.

Patients using cannabis tended to be younger, living in large cities, and more aware of the legal and clinical aspects of medicinal cannabis. Sixty-five percent of non-users were interested in using medicinal cannabis, but lack of knowledge and fear of side effects were reported as main reasons for not trying it.

“Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD,” noted Prof. Dr. med. Buhmann. “Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable.”

“Cannabis intake might be related to a placebo effect because of high patient expectations and conditioning, but even that can be considered as a therapeutic effect. It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate studies are urgently needed,” he concluded.

Bastiaan R. Bloem, MD, PhD, Director, Radboudumc Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands, and Co-Editor-in Chief of the Journal of Parkinson’s Disease, added: “These findings are interesting in that they confirm a widespread interest among patients in the use of cannabis as a potential treatment for people living with PD. It is important to emphasize that more research is needed before cannabis can be prescribed as a treatment, and that guidelines currently recommend against the use of cannabis, even as self-medication, because the efficacy is not well established, and because there are safety concerns (adverse effects include among others sedation and hallucinations). As such, the present paper mainly serves to emphasize the need for carefully controlled clinical trials to further establish both the efficacy and safety of cannabis treatment.”

Medical Marijuana NY-Based Biotech Company Enters Clinical Trials

NEW YORK:  AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus cannabidiol (CBD) gum at Wageningen University in the Netherlands.

Human Clinical Trials Detail Include:

  • Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies
  • The amount of the hemp oil CBD gum is set at 50mg of CBD per serving
  • Per the trial protocol patients can use up to 6 chewing gums a day to control their stomach cramps, bloating, pain and other symptom
  • The main study outcome is perceived pain reduction. Furthermore, the study will record general relief and change in stool frequenc

The clinical trial will include a group of 40 patients, age 18-65, diagnosed with IBS according to ROME III criteria to determine the effectiveness of CanChew Plus in alleviating IBS symptoms

“The clinical trial at Wageningen University is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum, and we look forward to sharing updates from the trial with you,” added Anastassov.

 “With positive outcome from the IBS clinical trial, we will be ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD); Ulcerative colitis and Crohn’s disease. We are committed to finding research-based cannabinoid

Holland’s New Marijuana Laws Are Changing Old Amsterdam

NETHERLANDS:  The last time Derrick Bergman came to Amsterdam to buy cannabis, he did so behind a locked door with a long, thick curtain obscuring his activity from the canal-lined residential street outside, in the quiet Lastage neighborhood. The secretary of the Netherlands’s Union for the Abolition of Cannabis Prohibition, Bergman comes here to weekly gatherings of a two-month-old—and seriously clandestine—“cannabis social club” called the Tree of Life, because it’s the only place in town he can find one of his favorite strains: Super Silver Haze.

Since 1976, authorities across the Netherlands have chosen to openly ignore that cannabis use is illegal here, and they prosecute no one in possession of less than five grams of marijuana for personal use. The policy, called gedoogbeleid, is known as the “Dutch model,” and it’s why hundreds of “coffee shops” sprung up across Amsterdam and the Netherlands, luring marijuana connoisseurs from across the globe to one of the few places they could roll and smoke a joint without fear. But that’s no longer the case.

While U.S. States Relax Marijuana Laws, Pot Haven Netherlands Cracks Down, With Mixed Success

NETHERLANDS: A young man at a bus stop hisses at a passer-by: “What you looking for … marijuana?” It’s a scene of street peddling that the Netherlands hoped to stamp out in the 1970s when it launched a policy of tolerating “coffee shops” where people could buy and smoke pot freely.

But Maastricht’s street dealers are back, local residents complain. And the reason is a crackdown on coffee-shops triggered by another problem: Pot tourists who crossed the border to visit the cafes and made a nuisance of themselves by snarling traffic, dumping litter and even urinating in the streets. [Read more…]

Forget Marijuana Madness: Could Marijuana Treat Your Depression

NETHERLANDS: Depending on who you listen to, marijuana could be the solution for whatever ails you or your ultimate demise; or it could make you dumb and sick. We have a tendency to believe the research not funded by biased parties in support of federal marijuana prohibition—the research that shows cannabis may reduce the risk of Alzheimer’s and obesity, kill cancer cells, and even treat depression. [Read more…]

Report: Dutch Lessons For U.S. Marijuana Policy

NETHERLANDS: A new report from the Open Society Global Drug Policy Program finds that the Dutch have effectively separated the markets for marijuana and hard drugs, leading to the “lowest rate of problem drug use in Europe”.

The report titled “Coffee Shops and Compromise: Separated Illicit Drug Markets in the Netherlands” finds that only 14 percent of Dutch cannabis users say they can get other drugs from their weed dealer. By contrast in Sweden, 52 percent of pot smokers say they can buy other drugs from their pot sources. The Netherlands has the lowest rate of problem drug use in Europe, the report finds. [Read more…]